Spoken Alpha
FBIO
Fortress Biotech, Inc.
Overview
Fortress Biotech, Inc is a Healthcare company operating in Biotechnology with a $102.3M market cap.
FBIO beat consensus EPS by 1.0% in Q1 FY2026, reported Mar 30, 2026.
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q1 FY20262026-03-30EPS$2.82 vs $-0.22+100.0%Rev$16.0M vs ——EODHD
- Q4 FY20252025-12-30EPS$-0.21 vs $0.11-100.0%Rev$16.1M vs ——EODHD
- Q3 FY20252025-11-13EPS$0.11 vs $-0.01+100.0%Rev$17.6M vs ——EODHD
- Q2 FY20252025-08-13EPS$0.45 vs $0.07+100.0%Rev$16.4M vs ——EODHD
- Q1 FY20252025-05-12EPS$-0.48 vs $-0.44-9.1%Rev$13.1M vs ——EODHD
- Q4 FY20242025-03-25EPS$-0.30 vs $-0.75+60.1%Rev$15.1M vs ——EODHD
- Q3 FY20242024-09-29EPS$-0.76 vs $-0.27-100.0%Rev$14.6M vs ——EODHD
- Q2 FY20242024-08-12EPS$-0.73 vs $-1.22+40.2%Rev$14.9M vs ——EODHD
- Q1 FY20242024-05-14EPS$-1.03 vs $-1.73+40.5%Rev$13.0M vs ——EODHD
- Q4 FY20232024-03-27EPS$-1.28 vs $-1.97+35.0%Rev$19.9M vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.94 vs $-3.21+70.7%Rev$34.8M vs ——EODHD
- Q2 FY20232023-08-13EPS$-0.24 vs $-0.23-4.3%Rev$17.4M vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.21 vs $-0.20-5.0%Rev$12.4M vs ——EODHD
- Q4 FY20222023-03-28EPS$-0.30 vs $-0.22-36.4%Rev$16.4M vs ——EODHD
- Q3 FY20222022-11-13EPS$-0.25 vs $-0.27+7.4%Rev$16.5M vs ——EODHD
- Q2 FY20222022-08-10EPS$-0.24 vs $-0.21-14.3%Rev$18.9M vs ——EODHD
- Q1 FY20222022-05-11EPS$-0.18 vs $-0.28+35.7%Rev$23.9M vs ——EODHD
- Q4 FY20212022-03-22EPS$-0.38 vs $0.18-100.0%Rev$18.3M vs ——EODHD
- Q3 FY20212021-11-11EPS$-0.14 vs $-0.08-75.0%Rev$21.1M vs ——EODHD
- Q2 FY20212021-08-15EPS$-0.29 vs $-0.12-100.0%Rev$17.8M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-03-30 | $2.82 | $-0.22 | +100.0% | $16.0M | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-0.21 | $0.11 | -100.0% | $16.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $0.11 | $-0.01 | +100.0% | $17.6M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $0.45 | $0.07 | +100.0% | $16.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.48 | $-0.44 | -9.1% | $13.1M | — | — | EODHD |
| Q4 FY2024 | 2025-03-25 | $-0.30 | $-0.75 | +60.1% | $15.1M | — | — | EODHD |
| Q3 FY2024 | 2024-09-29 | $-0.76 | $-0.27 | -100.0% | $14.6M | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.73 | $-1.22 | +40.2% | $14.9M | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-1.03 | $-1.73 | +40.5% | $13.0M | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-1.28 | $-1.97 | +35.0% | $19.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.94 | $-3.21 | +70.7% | $34.8M | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.24 | $-0.23 | -4.3% | $17.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.21 | $-0.20 | -5.0% | $12.4M | — | — | EODHD |
| Q4 FY2022 | 2023-03-28 | $-0.30 | $-0.22 | -36.4% | $16.4M | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.25 | $-0.27 | +7.4% | $16.5M | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.24 | $-0.21 | -14.3% | $18.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.18 | $-0.28 | +35.7% | $23.9M | — | — | EODHD |
| Q4 FY2021 | 2022-03-22 | $-0.38 | $0.18 | -100.0% | $18.3M | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.14 | $-0.08 | -75.0% | $21.1M | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.29 | $-0.12 | -100.0% | $17.8M | — | — | EODHD |
Source: EODHD. FBIO reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks FBIO's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $1.26 | $1.42 | -11.5% | +6.1% | +3.3% |
| Q4 FY2025 | $1.40 | $1.53 | -8.3% | 0.0% | +1.4% |
| Q3 FY2025 | $1.45 | $1.59 | -9.0% | +7.2% | +9.8% |
| Q2 FY2025 | $1.56 | $1.76 | -11.5% | +6.5% | +6.1% |
| Q1 FY2024 | $1.45 | $1.72 | -15.6% | +1.7% | +0.1% |
| Q4 FY2024 | $1.51 | $1.71 | -11.7% | +6.9% | +4.6% |
| Q3 FY2024 | $1.62 | $1.75 | -7.6% | +6.8% | +6.7% |
| Q2 FY2024 | $1.58 | $1.70 | -7.0% | +2.4% | +4.4% |
| Q1 FY2023 | $1.39 | $1.61 | -13.6% | +6.6% | +9.0% |
| Q4 FY2023 | $1.59 | $1.75 | -9.0% | -2.1% | -3.0% |
Guidance change history
Sample- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
- Q1 FY2024Lowered2024-04-15
- Q4 FY2024Lowered2024-13-15
- Q3 FY2024Lowered2024-10-15
- Q2 FY2024Lowered2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Lindsay A Rosenwald MdCEO1 yr 9 mono recorded callsCurrentSample
CEO since 2024 • 2/4 beats (50%) • last guidance cut Q1 FY2025
- David JinCFO1 yr 11 mono recorded callsCurrentSample
CFO since 2024 • 3/4 beats (75%) • guidance suspended Q3 FY2025
- Michael S WeissExecutive Vice Chairman1 yr 5 mono recorded callsCurrentSample
OTHER since 2025 • 2/2 beats (100%) • guidance suspended Q2 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for FBIO.
$ curl https://api.spokenalpha.com/v1/companies/FBIOFAQ
Frequently asked about FBIO
Where can I find Fortress Biotech, Inc.'s (FBIO) earnings call transcripts?
Spoken Alpha indexes FBIO's earnings call transcripts at https://spokenalpha.com/companies/FBIO. Each call links to attributed speakers and parsed analyst Q&A. Fortress Biotech, Inc.'s own investor relations page is at https://www.fortressbiotech.com/investors.
When was Fortress Biotech, Inc.'s most recent earnings call?
Fortress Biotech, Inc. (FBIO) held its most recent earnings call on 2025-11-12, covering fiscal Q3 2025.
What sector is FBIO in?
Fortress Biotech, Inc. (FBIO) operates in the Healthcare sector (Biotechnology industry).